Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Immuno-Oncology Europe 2019

Immuno-Oncology Europe 2019

Keynote Speakers

Stephen Beers
Professor of Immunology and Immunotherapy, University of Southampton

Sara Colombetti
Global Head Oncology Discovery Pharmacology, pharma Research and Early Development (pRED), Roche Innovation Center Zürich

Elena Menietti
Scientist, Oncology Discovery Pharmacology, pharma Research and Early Development (pRED), Roche Innovation Center Zürich

Graham Pockley
Director and Professor, John van Geest Cancer Research Centre, Nottingham Trent University, CEO, multimmune GmbH

Ed Schuuring
Professor in Molecular Oncological Pathology, University Medical Center Groningen


Immuno-Oncology represents a portfolio of approaches aimed at deploying the immune system against tumor targets in vivo.  There is a growing body of scientific and clinical evidence that these approaches are yielding clinically-actionable strategies for cancer treatment.

The SelectBIO Immuno-Oncology Europe 2019 is a Summit which brings together the key opinion leaders in the immunotherapy and tumor immunology fields to address the most up-to-date strategies for immune therapy and means by which immunotherapies may be rationally-combined with more traditional anti-cancer therapeutics.  This field is converging with biofluid biopsies/liquid biopsies and therefore this conference brings together these two disciplines as they are co-evolving.

This conference also addresses biomarkers and companion diagnostics (CDx) which can be utilized to "target patient populations" suitable for immunotherapies.

Presentations from researchers and clinician-scientists at this conference discuss the most recent themes and clinical data.

Information and Local Registration Facilities for this Summit are Also Available In:

Japanese  |  Korean  |  Chinese (Simplified)  |  Chinese (Traditional)

Agenda Topics

  • Biomarkers & Companion Diagnostics for Immunotherapy
  • Checkpoint and Non-Checkpoint Immunotherapies
  • Chimeric Antigen Receptor (CAR) T-Cells in Cancer Immunotherapy
  • Combination Cancer Immunotherapy
  • Costimulatory Molecules for Immunological Activation & Therapeutic Intervention
  • Immunomodulatory Antibodies
  • Preclinical Animal Models for Immuno-Oncology
  • Small Molecules in Cancer Immune Therapy
  • Targeting Signaling Pathways in Cancer as Therapeutic Intervention
  • Targeting the Tumor Microenvironment

Sponsorship and Exhibition Opportunities

Jeff Fan, Exhibition Manager

Distinguished Faculty

Jeanette H W Leusen, Associate Professor & Head of Immunotherapy Group, University Medical Center Utrecht
David Giljohann, CEO, Exicure
RJ Tesi, CEO/CMO, Inmune Bio Inc
Radhakrishnan Iyer, Co-Founder & Chief Scientific Officer, Spring Bank Pharmaceuticals, Inc.
Walter Ferlin, CSO, Light Chain Bioscience
CJ Barnum, Director of Neuroscience, INmune Bio, Inc.
Philip Arlen, President and CEO, Precision Biologics, Inc
Mark Cragg, Professor and Chair in Experimental Cancer Biology, Centre for Cancer Immunology, University of Southampton, Southampton General Hospital
Saso Cemerski, Senior Director, CUE Biopharma
James Legg, Senior Vice President of Research, Crescendo Biologics
Lorena Lerner, Vice President, Molecular Biology & Virology, Oncorus
Johan Baeck, VP, Clinical Development & Medical Affairs, Jounce Therapeutics

Corporate SponsorsWeb SponsorsOffical Journal PartnerNetworking
Drug Discovery WorldU-Networks